Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 354 results for "Victoza"

Novo Nordisk abandons Victoza submission after mixed T1D results
Pharmafile

Novo Nordisk abandons Victoza submission after mixed T1D results

Novo Nordisk has been forced to scrap plans to expand its licence for Victoza to include adults with type 1 diabetes following disappointing results in a Phase III study. The Danish firm had hoped to grow its diabetes market share by extending the ... Pharmafile, 4 days ago
[x]  
TeleTrader.com

Premarket Biotech Digest: Which Cancer Drug, MannKind's Future, Victoza Trial

Dr De's Opening Thoughts: Which company leads cancer sales in 2020? By 2020, according to consensus estimates , of the 20 top drugs in cancer, 7 will be from Roche (OTCQX:RHHBY), 2 each from Celgene (CELG) and Bristol Myers Squibb, and 1 each for ...
 TeleTrader.com1 week ago

Warning: Don't Share Insulin Pens

If you use insulin pens or take other injected diabetes medications (such as Symlin, Victoza, or Byetta), don't share your medication pen with anyone else—even if youve attached a new needle. Blood can get stuck inside the pen from previous use ...
 Diabetes Forecast2 months ago

ELI LILLY : Study: Once-Weekly Trulicity dulaglutide Provides Greater Blood Sugar Reduction Compared to Once-Daily Victoza® liraglutide in Japanese Patients...

Study: Once-Weekly Trulicity dulaglutide Provides Greater Blood Sugar Reduction Compared to Once-Daily Victoza® liraglutide in Japanese Patients after 52 weeks By a News Reporter-Staff News Editor at Diabetes Week -- Results from a new study of ...
 4 Traders2 months ago Eli Lilly announces encouraging results from type 2 diabetes study  Individual.com2 months ago
WKRB News

Novo Nordisk A/S Upgraded to Buy by Zacks (NVO)

Zacks upgraded shares of Novo Nordisk A/S (NYSE:NVO) from a hold rating to a buy ratingin a research report report published onFriday, ARN reports. The firm currently has $63.00 price target on the stock. According to Zacks, Novo Nordisk's ...
 WKRB News1 day ago Novo Nordisk A/S Upgraded by Zacks to Buy (NVO)  American Banking News - Stock Ratings2 days ago Novo Nordisk A/S Upgraded at Zacks (NVO)  SleekMoney2 months ago Novo Nordisk A/S Stock Rating Upgraded by Zacks (NVO)  American Banking News2 months ago
SleekMoney

Stock Analysts Upgrades for August, 28th (CB, CM, CSIQ, DH, DST, GES, ITW, KERX, NGD, NVO)

Stock Analysts upgrades for Friday, August 28th: Chubb Corp (NYSE:CB) was upgraded by analysts at Zacks from a hold rating to a buy rating. They currently have $136.00 price target on the stock. According to Zacks, Chubb's has agreed to be ...
 SleekMoney2 days ago
Sys-Con Media

Global Market Study on Biological Drugs: North America to Witness Highest Growth By 2020

NEW YORK , Aug. 27, 2015 /PRNewswire/ -- Biological drugs are typically derived from living cells and are used in the prevention and treatment of various diseases such as cancer, blood disorders, auto-immune diseases and other medical conditions.
 Sys-Con Media3 days ago Global Biological Drugs Market Will Reach US$ 287.1 Billion in 2020 by Persistence Market Research  Marketplace2 months ago
[x]  
US News & World Report

The New Obesity Drugs: an Rx for Weight Loss?

People who need to lose a significant amount of weight and there are a lot of them finally have more medical options. After a string of disappointments, the Food and Drug Administration has lately approved four drugs that can aid in weight loss ...
 US News & World Report4 days ago Weight Loss Strategies for Diabetes  WebMD1 month ago New Weight loss drugs appear, but no magic pill yet  Social Dashboard1 month ago New weight loss drugs, but no magic pill  Channel40001 month ago
[x]  
European Pharmaceutical Review

Disappointing results for liraglutide in type 1 diabetes

Novo Nordisk has announced headline results from the second and final Phase 3a trial with liraglutide as adjunct therapy to insulin for people with type 1 diabetes. ADJUNCT ONE is a randomised, double-blind, placebo-controlled trial investigating ...
 European Pharmaceutical Review5 days ago Novo Nordisk completes second and final phase 3a trial with liraglutide as adjunct therapy to insulin for people with type 1 diabetes (NN9211)  EuroInvestor6 days ago
MedPage Today

Morning Break: Skip the Water; Don't Drink Urine; DIY Erectile Tx a Bummer

The last known Ebola patient in Sierra Leone was discharged Monday , according to Reuters , beginning a 42-day countdown to the outbreak's official end there. Children as young as 1 year may take eltrombopag (Promacta) for chronic idiopathic ...
 MedPage Today5 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - Victoza
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less